Study Details First Artificial Intelligence Tool to Help Labs Rule-out COVID-19

Hospital-based laboratories and doctors at the front line of the COVID-19 pandemic might soon add artificial intelligence to their testing toolkit. A recent study conducted with collaborators from the University of Vermont and Cedars-Sinai describes the performance of Biocogniv's new AI-COVID™ software. The team found high accuracy in predicting the probability of COVID-19 infection using routine blood tests, which can help hospitals reduce the number of patients referred for scarce PCR testing.

"Nine months into this pandemic, we now have a better understanding of how to care for patients with COVID-19," says lead author and University of Vermont Assistant Professor Timothy Plante, M.D., M.H.S., "but there's still a big bottleneck in COVID-19 diagnosis with PCR testing."

PCR testing is the current standard diagnostic for COVID-19, and requires specific sampling, like a nasal swab, and specialized laboratory equipment to run.

Biocogniv Chief Operating Officer Tanya Kanigan, Ph.D., says, "According to data from over 100 US hospitals, the national average turnaround time for COVID-19 tests ordered in emergency rooms is above 24 hours, far from the targeted one-hour turnaround."

Complete Blood Count and Complete Metabolic Panels are common laboratory tests ordered by emergency departments and have a rapid turnaround time. These tests provide insight into the immune system, electrolytes, kidney, and liver. The researchers were able to train a model that analyzes changes in these routine tests and assigns a probability of the patient being COVID-19 negative with high accuracy.

"AI-COVID takes seconds to generate its informative result once these blood tests return, which can then be incorporated by the laboratory into its own test interpretation," says Jennifer Joe, M.D., an emergency physician in Boston, Mass. and Biocogniv's Chief Medical Officer. "In an efficient emergency department that prioritizes these routine blood tests, the door-to-result time could be under an hour."

Cedars-Sinai pulmonary and internal medicine specialist Victor Tapson, M.D., says such assistive tools that help physicians rule out possible diagnoses are familiar in emergency medicine.

"For example, a low D-dimer blood test can help us rule out clots in certain patients, allowing providers to skip expensive, often time-consuming diagnostics such as chest CT scans," says Tapson.

The Biocogniv team believes a secondary benefit of laboratories incorporating AI-COVID might be reduced time for traditional PCR results.

"With the help of AI-COVID, laboratories might relieve some of the testing bottleneck by helping providers better allocate rapid PCR testing for patients who really need it," says Joe.

The AI-COVID model was validated on real world data from Cedars-Sinai as well as on data from geographically and demographically diverse patient encounters from 22 U.S. hospitals, achieving an area under the curve (or AUC) of 0.91 out of 1.00.

"This enables the model to achieve a high sensitivity of 95% while maintaining moderate specificity of 49%, which is very similar to the performance of other commonly used rule-out tests," says Biocogniv Chief Scientific Officer George Hauser, MD, a pathologist.

Biocogniv CEO Artur Adib, Ph.D., says, "I'm honored to have such an impressive team of medical scientists from the University of Vermont and Cedars-Sinai as collaborators in validating this timely model. AI has progressed considerably; the time is now to leverage this powerful tool for new healthcare breakthroughs, and we're glad to direct it to help hospital laboratories and providers combat the current COVID-19 crisis."

Plante TB, Blau AM, Berg AN, Weinberg AS, Jun IC, Tapson VF, Kanigan TS, Adib AB.
Development and External Validation of a Machine Learning Tool to Rule Out COVID-19 Among Adults in the Emergency Department Using Routine Blood Tests: A Large, Multicenter, Real-World Study.
J Med Internet Res 2020. doi: 10.2196/24048

Most Popular Now

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...

AXREM and Highland Marketing Partner to …

AXREM represents member companies that collectively provide UK hospitals with most of their diagnostic medical imaging technology, and radiotherapy equipment. The association has seen substantial growth in recent years, with membership...